Axsome Therapeutics Financial Statements (AXSM)
|
|
Report date
|
|
|
06.11.2023 |
23.02.2024 |
06.05.2024 |
05.08.2024 |
12.11.2024 |
|
12.11.2024 |
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
57.8 |
71.5 |
75.0 |
87.2 |
104.8 |
|
338.5 |
Operating Income, bln rub |
|
|
-62.1 |
-98.1 |
-68.7 |
-78.0 |
-62.6 |
|
-307.5 |
EBITDA, bln rub |
? |
|
-60.4 |
-96.5 |
-65.4 |
-78.0 |
-60.6 |
|
-300.6 |
Net profit, bln rub |
? |
|
-62.2 |
-98.7 |
-68.4 |
-79.3 |
-64.6 |
|
-311.0 |
|
OCF, bln rub |
? |
|
-53.5 |
-30.4 |
-53.5 |
-30.1 |
-18.6 |
|
-132.6 |
CAPEX, bln rub |
? |
|
0.371 |
0.007 |
0.098 |
0.052 |
0.150 |
|
0.307 |
FCF, bln rub |
? |
|
-53.9 |
-30.4 |
-53.6 |
-30.2 |
-18.5 |
|
-132.6 |
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
OPEX, bln rub |
|
|
113.4 |
168.3 |
135.6 |
157.2 |
158.9 |
|
620.0 |
Cost of production, bln rub |
|
|
6.53 |
7.38 |
8.13 |
8.06 |
8.44 |
|
32.0 |
R&D, bln rub |
|
|
28.8 |
30.8 |
36.6 |
49.9 |
45.4 |
|
162.6 |
Interest expenses, bln rub |
|
|
0.757 |
0.702 |
1.08 |
1.30 |
1.98 |
|
5.06 |
|
Assets, bln rub |
|
|
600.9 |
588.2 |
545.7 |
548.2 |
561.5 |
|
561.5 |
Net Assets, bln rub |
? |
|
269.5 |
191.0 |
144.0 |
102.9 |
92.9 |
|
92.9 |
Debt, bln rub |
|
|
185.6 |
186.4 |
189.4 |
191.8 |
192.3 |
|
192.3 |
Cash, bln rub |
|
|
416.6 |
386.2 |
331.4 |
315.7 |
327.3 |
|
327.3 |
Net debt, bln rub |
|
|
-231.0 |
-199.8 |
-142.0 |
-123.9 |
-135.0 |
|
-135.0 |
|
Ordinary share price, rub |
|
|
69.9 |
79.6 |
79.8 |
80.5 |
89.9 |
|
64.4 |
Number of ordinary shares, mln |
|
|
47.1 |
47.3 |
47.4 |
47.6 |
48.1 |
|
48.1 |
|
Market cap, bln rub |
|
|
3 293 |
3 767 |
3 782 |
3 830 |
4 326 |
|
3 101 |
EV, bln rub |
? |
|
3 062 |
3 567 |
3 640 |
3 706 |
4 191 |
|
2 966 |
Book value, bln rub |
|
|
203 |
126 |
80 |
41 |
32 |
|
32 |
|
EPS, rub |
? |
|
-1.32 |
-2.08 |
-1.44 |
-1.67 |
-1.34 |
|
-6.46 |
FCF/share, rub |
|
|
-1.14 |
-0.64 |
-1.13 |
-0.63 |
-0.38 |
|
-2.75 |
BV/share, rub |
|
|
4.30 |
2.65 |
1.69 |
0.86 |
0.67 |
|
0.67 |
|
EBITDA margin, % |
? |
|
-104.5% |
-135.0% |
-87.3% |
-89.5% |
-57.8% |
|
-88.8% |
Net margin, % |
? |
|
-107.6% |
-137.9% |
-91.1% |
-91.0% |
-61.7% |
|
-91.9% |
FCF yield, % |
? |
|
-4.34% |
-3.87% |
-5.11% |
-4.39% |
-3.06% |
|
-4.28% |
ROE, % |
? |
|
-76.9% |
-125.3% |
-205.8% |
-300.0% |
-334.7% |
|
-334.7% |
ROA, % |
? |
|
-34.5% |
-40.7% |
-54.3% |
-56.3% |
-55.4% |
|
-55.4% |
|
P/E |
? |
|
-15.9 |
-15.7 |
-12.8 |
-12.4 |
-13.9 |
|
-9.97 |
P/FCF |
|
|
-23.0 |
-25.9 |
-19.6 |
-22.8 |
-32.6 |
|
-23.4 |
P/S |
? |
|
14.7 |
13.9 |
15.1 |
13.1 |
12.8 |
|
9.16 |
P/BV |
? |
|
16.3 |
30.0 |
47.1 |
94.1 |
133.7 |
|
95.8 |
EV/EBITDA |
? |
|
-17.4 |
-16.3 |
-13.0 |
-12.3 |
-13.9 |
|
-9.87 |
Debt/EBITDA |
|
|
1.31 |
0.91 |
0.51 |
0.41 |
0.45 |
|
0.45 |
|
R&D/CAPEX, % |
|
|
7 754% |
440 043% |
37 335% |
95 871% |
30 259% |
|
52 975% |
|
CAPEX/Revenue, % |
|
|
0.64% |
0.01% |
0.13% |
0.06% |
0.14% |
|
0.09% |
|
Axsome Therapeutics shareholders |